Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinson's disease
Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinson's disease
No Thumbnail Available
Files
There are no files associated with this item.
Date
2014
Authors
Grolez, Guillaume
Meguig, Sayah
Moreau, Caroline
Sablonniere, Bernard
Strubi-Vuiklhaume, Isabelle
Ryckewaert, G.
Jissendi, Patrice
Hopes, L.
Editors
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
DOI (citable link)
International patent number
Link to the license
EU project number
Project
Open Access publication
Collections
Title in another language
Publication type
Journal article
Publication status
Published
Published in
Movement Disorders ; 29 (2014), Suppl 1. - pp. S241. - Wiley. - ISSN 0885-3185. - eISSN 1531-8257
Abstract
Objective: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Our aim was to evaluate the interaction between iron chelation response on clinical, biological and MRI parameters and the variable ferroxidase activity in relation with the ceruloplasmin polymorphism D544E.
Background: In PD, excess iron is detected primarily in the substantia nigra (SN), where dopaminergic neurons are exposed to high levels of Reactive oxygen species (ROS). Excess labile iron can further worsen neuronal functions and triggered apoptosis by Fenton reaction. By oxidation of toxic ferrous (Fe2+) iron into ferric (Fe3+) iron, ceruloplasmin allows iron transportation between blood and cells. Ceruloplasmin metabolism disturbances, notably through lower ferroxidase activity of AT polymorphism, may increase brain iron overload.
Methods: A pilot, double blind, placebo‐controlled randomized clinical trial with a 6‐month delayed‐start paradigm, was set in 40 early‐stage patients on stabilized dopamine regimens with deferiprone (oral administration of 30mg/kg/day). The effect of deferiprone was analyzed according to the ceruloplasmine genotypes (AT versus AA), on motor UPDRS, MRI R2* (T2*=1/R2*) sequences (indirect assessment of iron overload) and the plasmatic ceruloplasmin, iron serum, transferrin and ferritin levels.
Results: Early‐start patients (n = 19) compared to delayed start patients (n = 18) (37/40 completed) responded significantly earlier and sustainably to treatment in both SN iron deposits (R2* MRI) and motor UPDRS (p < 0.03 and p < 0.04, respectively). After 12 months of deferiprone, the AT group (n=5) had a greater clinical improvement, an increase in ceruloplasmin levels and a reduction of R2* value as compared with AA group (n=32).
Conclusions: A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. The benefit appeared higher in patients carrying the AT polymorphism, suggesting that patients with lower ceruloplasmin activity may be at higher risk of iron metabolism dysfunction and may require stronger iron chelation. These results warrant confirmation with multicenter study on a larger population and longer time.
Background: In PD, excess iron is detected primarily in the substantia nigra (SN), where dopaminergic neurons are exposed to high levels of Reactive oxygen species (ROS). Excess labile iron can further worsen neuronal functions and triggered apoptosis by Fenton reaction. By oxidation of toxic ferrous (Fe2+) iron into ferric (Fe3+) iron, ceruloplasmin allows iron transportation between blood and cells. Ceruloplasmin metabolism disturbances, notably through lower ferroxidase activity of AT polymorphism, may increase brain iron overload.
Methods: A pilot, double blind, placebo‐controlled randomized clinical trial with a 6‐month delayed‐start paradigm, was set in 40 early‐stage patients on stabilized dopamine regimens with deferiprone (oral administration of 30mg/kg/day). The effect of deferiprone was analyzed according to the ceruloplasmine genotypes (AT versus AA), on motor UPDRS, MRI R2* (T2*=1/R2*) sequences (indirect assessment of iron overload) and the plasmatic ceruloplasmin, iron serum, transferrin and ferritin levels.
Results: Early‐start patients (n = 19) compared to delayed start patients (n = 18) (37/40 completed) responded significantly earlier and sustainably to treatment in both SN iron deposits (R2* MRI) and motor UPDRS (p < 0.03 and p < 0.04, respectively). After 12 months of deferiprone, the AT group (n=5) had a greater clinical improvement, an increase in ceruloplasmin levels and a reduction of R2* value as compared with AA group (n=32).
Conclusions: A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. The benefit appeared higher in patients carrying the AT polymorphism, suggesting that patients with lower ceruloplasmin activity may be at higher risk of iron metabolism dysfunction and may require stronger iron chelation. These results warrant confirmation with multicenter study on a larger population and longer time.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690
GROLEZ, Guillaume, Sayah MEGUIG, Caroline MOREAU, Bernard SABLONNIERE, Isabelle STRUBI-VUIKLHAUME, G. RYCKEWAERT, Patrice JISSENDI, L. HOPES, Marcel LEIST, Dominik PÖLTL, 2014. Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinson's disease. In: Movement Disorders. Wiley. 29(Suppl 1), pp. S241. ISSN 0885-3185. eISSN 1531-8257. Available under: doi: 10.1002/mds.25914BibTex
@article{Grolez2014Modif-52646, year={2014}, doi={10.1002/mds.25914}, title={Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinson's disease}, number={Suppl 1}, volume={29}, issn={0885-3185}, journal={Movement Disorders}, author={Grolez, Guillaume and Meguig, Sayah and Moreau, Caroline and Sablonniere, Bernard and Strubi-Vuiklhaume, Isabelle and Ryckewaert, G. and Jissendi, Patrice and Hopes, L. and Leist, Marcel and Pöltl, Dominik}, note={Poster Presentation Article Number: Meeting Abstract 652} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52646"> <dc:creator>Meguig, Sayah</dc:creator> <dc:contributor>Grolez, Guillaume</dc:contributor> <dc:contributor>Meguig, Sayah</dc:contributor> <dc:creator>Leist, Marcel</dc:creator> <dc:contributor>Moreau, Caroline</dc:contributor> <dc:creator>Strubi-Vuiklhaume, Isabelle</dc:creator> <dc:creator>Hopes, L.</dc:creator> <dc:contributor>Leist, Marcel</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:contributor>Strubi-Vuiklhaume, Isabelle</dc:contributor> <dc:rights>terms-of-use</dc:rights> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-01T08:43:19Z</dcterms:available> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-01T08:43:19Z</dc:date> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52646"/> <dc:contributor>Pöltl, Dominik</dc:contributor> <dcterms:issued>2014</dcterms:issued> <dcterms:title>Modifying effect of ceruloplasmin polymorphism on iron chelation response in Parkinson's disease</dcterms:title> <dc:creator>Moreau, Caroline</dc:creator> <dc:creator>Ryckewaert, G.</dc:creator> <dc:creator>Grolez, Guillaume</dc:creator> <dc:contributor>Hopes, L.</dc:contributor> <dc:language>eng</dc:language> <dc:creator>Sablonniere, Bernard</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Jissendi, Patrice</dc:creator> <dc:contributor>Sablonniere, Bernard</dc:contributor> <dcterms:abstract xml:lang="eng">Objective: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Our aim was to evaluate the interaction between iron chelation response on clinical, biological and MRI parameters and the variable ferroxidase activity in relation with the ceruloplasmin polymorphism D544E.<br /><br />Background: In PD, excess iron is detected primarily in the substantia nigra (SN), where dopaminergic neurons are exposed to high levels of Reactive oxygen species (ROS). Excess labile iron can further worsen neuronal functions and triggered apoptosis by Fenton reaction. By oxidation of toxic ferrous (Fe2+) iron into ferric (Fe3+) iron, ceruloplasmin allows iron transportation between blood and cells. Ceruloplasmin metabolism disturbances, notably through lower ferroxidase activity of AT polymorphism, may increase brain iron overload.<br /><br />Methods: A pilot, double blind, placebo‐controlled randomized clinical trial with a 6‐month delayed‐start paradigm, was set in 40 early‐stage patients on stabilized dopamine regimens with deferiprone (oral administration of 30mg/kg/day). The effect of deferiprone was analyzed according to the ceruloplasmine genotypes (AT versus AA), on motor UPDRS, MRI R2* (T2*=1/R2*) sequences (indirect assessment of iron overload) and the plasmatic ceruloplasmin, iron serum, transferrin and ferritin levels.<br /><br />Results: Early‐start patients (n = 19) compared to delayed start patients (n = 18) (37/40 completed) responded significantly earlier and sustainably to treatment in both SN iron deposits (R2* MRI) and motor UPDRS (p < 0.03 and p < 0.04, respectively). After 12 months of deferiprone, the AT group (n=5) had a greater clinical improvement, an increase in ceruloplasmin levels and a reduction of R2* value as compared with AA group (n=32).<br /><br />Conclusions: A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD. The benefit appeared higher in patients carrying the AT polymorphism, suggesting that patients with lower ceruloplasmin activity may be at higher risk of iron metabolism dysfunction and may require stronger iron chelation. These results warrant confirmation with multicenter study on a larger population and longer time.</dcterms:abstract> <dc:contributor>Ryckewaert, G.</dc:contributor> <dc:contributor>Jissendi, Patrice</dc:contributor> <dc:creator>Pöltl, Dominik</dc:creator> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> </rdf:Description> </rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Examination date of dissertation
Method of financing
Comment on publication
Poster Presentation
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
Yes
Refereed
No